You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 24, 2015

Front-of-Package Labeling in Thailand

Informed Counsel

Expanding waistlines and increasing health awareness have given rise to a consumer culture infatuated with well-being, not only in Thailand but all over the world. For producers, this means intense pressure to create healthy or healthier versions of their products. For the government—specifically the Thai Food and Drug Administration (FDA)—this means an obligation to implement and enforce stricter regulations on food and nutrition.

The Thai Perspective

As we move into an age where life is increasingly fast-paced, there is no reason why the food industry should be left behind. While nutritional labels are often displayed on the back of packaging, Front-of-Package (FOP) labeling has become popular among policy makers because it simplifies the most important information and places it where it is visible at first sight to the hurried consumer. In Thailand, the original 1998 Notification of the Ministry of Public Health (MOPH) implemented non-FOP nutritional labeling requirements which were mandatory for certain foods and voluntary for others. A survey conducted in 2009, however, concluded that the nutritional information was difficult to understand, which caused the FDA to make a number of changes.

In a series of subsequent ministerial notifications, the FDA implemented the Guideline Daily Amount (GDA) system of labeling, an FOP system that made GDA labels mandatory for snack products and certain ready-to-eat foods. The current GDA label breaks down nutritional information into four categories: calories, sugars, fats, and sodium. This requires producers to clearly state the nutrient content and percentage of recommended daily intake per package.

FOP Labeling Around the World

Countries around the world have also introduced policies which mirror the objectives of the GDA system of labeling to help consumers make the “smart” choice quickly. For example, the European Union takes the same approach as Thailand, basing its guidelines on the latest published scientific data on dietary requirements and recommendations. Similarly, the United States uses a voluntary Facts Up Front labeling system, which calls for a summary of calories, saturated fat, sodium, and sugar per serving on the front of various food and beverage products.

Singapore, on the other hand, uses the Healthier Choice Symbol, an interpretive nutrition logo which distinguishes products that are lower in saturated fat and trans fat, sodium, and sugar, but higher in whole grains, fiber, and other healthy nutrients. Nutrition guidelines are set according to each product category. There are 12 main product categories and more than 70 subcategories. In addition, there are variants including the Healthier Snack Symbol and the Healthier Ingredient Symbol.

Australia and New Zealand use the Daily Intake Guide and the Health Star Rating. The Daily Intake Guide is a voluntary scheme which uses a set of reference values for acceptable levels of intake for energy and a variety of nutrients, sugars, protein, fat, fiber, and sodium, to name a few. The Health Star Rating system was developed to make it easier for consumers to compare similarly packaged food and therefore make healthier decisions. It ranks products on a scale from half a star to five stars based on their nutritional profile which includes, for example, energy, saturated fat, and sodium. This system of labeling is a hybrid of the GDA system used by Thailand, the European Union, and the United States, as well as the Healthier Choice Symbol used by Singapore.

The Future of FOP Labeling

The food and beverage community has pushed to revamp the current FOP labeling scheme in Thailand. Currently, the National Food Committee, a subcommittee of the Thai FDA, is working to add to the present FOP GDA labeling scheme, but the additions have yet to be announced. It is known, however, that use of the new FOP label will be voluntary and presently it is only being considered for certain foods. Some organizations are looking for inspiration in the “traffic light” nutritional labeling system, a system that uses the colors red, amber, and green to indicate high, acceptable, and low levels of fat, saturated fats, sugar, and salt in various products. Foods with “green” indicators are healthier than foods with “red” indicators, while foods with “amber” indicators fall in between.

The Federation of Thai Industries Food Group has supported the use of GDA nutrition labels and is determined to become involved in educating consumers about the GDA system of labeling. It prefers the GDA system of labeling to a color-coded system or an interpretive nutritional logo because these are sometimes misleading and vague and often do not comprehensively take into account different nutritional needs.

The good news is that the industry has been invited to participate in the development of a new scheme which producers can both contribute to and benefit from. With the correct industry input, FOP labeling should offer consumers informative nutritional information that is apt for a fast-paced world.

RELATED INSIGHTS​ 

June 17, 2026
Thailand’s new labeling requirements for medical devices, which include for the first time a unique device identification (UDI) requirement for software as a medical device (SaMD), take effect on June 20, 2026. The Notification of the Ministry of Public Health regarding Criteria, Methods, and Conditions on Labeling and Instructions for Use for Medical Devices 2025, which replaces a similar notification from 2020, was published in the Government Gazette on December 22, 2025. To ensure clarity, modernity, and patient safety, the regulation requires domestic manufacturers and importers to provide labels and instructions for use (IFU) that are clearly legible, complete, and free of false or misleading claims. It also permits IFU to be provided in electronic format, such as via QR codes, websites, or other digital channels—directly relevant to SaMD, where physical labels are impractical and electronic presentation is the natural medium. The notification distinguishes two categories for labeling language. Home-use medical devices (for lay users outside healthcare facilities) must have labels and IFU in Thai. Professional-use medical devices may display labels and documentation in either Thai or English. This distinction is significant for SaMD developers: software intended for clinical professionals may use English-language interfaces and IFU, while consumer-facing health applications must provide Thai-language content. Labeling and UDI Requirements Labels and IFU must include, at a minimum: Product name and intended purpose Quantity or volume Name and address of domestic manufacturer or importer Thai FDA approval number Lot, version, or serial number Manufacturing date and expiry date For SaMD, the version number requirement is particularly relevant. The regulation also mandates display of a UDI code for SaMD in risk category 2 (moderate-risk), category 3 (moderate- to high-risk), and category 4 (high-risk), according to Thailand’s medical device risk classification system (which complies with the ASEAN Medical Device Directive and the EU
June 5, 2026
On May 25, 2026, Vietnam’s Ministry of Health issued Circular No. 16/2026/TT-BYT governing free-of-charge medicine support programs for medical establishments (Circular 16). Circular 16 will take effect on July 10, 2026, replacing Circular No. 31/2018/TT-BYT, which currently regulates the same subject matter. Circular 16 introduces several significant changes compared to the existing legal framework. Removal of Prior Approval Requirement Under the current regulations, free-of-charge medicine support programs are divided into two categories: (1) entirely free-of-charge provision of medicines for all types of drugs and (2) partially free-of-charge provision applicable only to brand-name drugs under patent protection or drugs whose generic products with identical active ingredients and dosage forms are available in Vietnam. Under the current regulations, partially free-of-charge programs are subject to mandatory registration with the competent authority, while entirely free-of-charge programs could be implemented without prior approval. A key reform under Circular 16 is that it stipulates only entirely free-of-charge medicine support programs applicable to all types of medicines, thereby eliminating the partially free-of-charge category. In addition, free-of-charge medicine support programs may be carried out solely based on a written agreement between the pharmaceutical company and the medical establishment, without any requirement for prior approval from competent authorities prior to implementation. Written Agreement Requirements Circular 16 requires the pharmaceutical company and medical establishment to enter into a written agreement in accordance with a prescribed template. This agreement must include the following compulsory information: Information on the supported medicines Form of support (entirely free-of-charge provision to patients) Quantity of medicines provided Target patient groups and applicable indications Duration of the program Rights and obligations of each party Transitional provisions on the protection of patients’ rights upon completion of the program The agreement may contain other contents as agreed by the parties, provided that these do not contradict applicable laws.
June 4, 2026
Indonesia’s Minister of Health has issued Decree No. HK.01.07/MENKES/301/2026 on the Affixation of Nutritional Labels and Health Information to Ready-to-Eat Processed Food Products. The decree came into force on April 14, 2026, and was issued to implement the Health Law and Minister of Health Regulation No. 3 of 2026 on Disease Control. The decree requires the inclusion of Nutri-Level labeling on the front-of-pack nutrition labeling (FOPNL) to indicate the product’s nutritional level based on the content of sugar, salt, and fat (“gula, garam dan lemak (GGL)”). Changes from 2024 Draft Regulation The Nutri-Level labeling was previously proposed in 2024 by the Indonesian FDA (BPOM) through a draft regulation concerning nutrition information. While the categories of Nutri-Level labeling remain the same in the issued decree, the content requirements of sugar, salt and fat in the decree are different from the earlier proposal introduced in the 2024 draft BPOM regulation. In addition, the decree has further specified that the content of fat in the Nutri-Level labeling is the content of saturated fat, not total fat as previously proposed in the 2024 draft. The decree requires Nutri-Level labeling to be implemented in beverage products, which is the same as previously proposed in the 2024 draft BPOM regulation. Other food products may gradually become subject to mandatory Nutri-Level labeling under future implementing regulations. Nutri-Level Labeling Food levels as shown by the Nutri-Level labeling are classified into four color-coded categories from A to D: Level A (lowest amount) in dark green Level B in light green Level C in yellow Level D (highest amount) in red The Nutri-Level labeling is represented by the following image. The requirements for each level for sugar, salt, and fat content, based on amounts per 100 milliliters of product in beverage form, are as follows. Nutri-Level information must be
May 29, 2026
Indonesia’s Food and Drug Authority (BPOM) has issued Regulation No. 7 of 2026 on Drug Promotion and Advertising, establishing an updated framework for promotional activities involving medicinal products in Indonesia. The regulation took effect on April 16, 2026, and supersedes BPOM Regulation No. 2 of 2021 on Drug Advertising Supervision. The new regulation maintains general principles for advertising content, including requirements that advertisements be objective, complete, and not misleading, as further detailed in its annex. It also confirms that advertisements for nonprescription drugs directed to the public must obtain prior approval from BPOM before publication and must be in Bahasa Indonesia. The regulation provides a more comprehensive framework governing how drug promotion is conducted, introducing several notable additions and changes, as described below. Procedure and Requirements for Drug Advertisement Approval To apply for a drug advertisement approval, applicants must create an online account through the dedicated portal SIAPIK. Advertisement approval is available only for registered drugs; unregistered drugs are not eligible for advertisement approval with BPOM. The application must include the advertisement design, along with a translation if the design contains any wording in a foreign language. The submission format varies by media type, requiring, for example, copies in the form of print advertisements for visual media, scripts for audio media, and storyboards for audiovisual media. For online media—including social media—submissions should include any captions, descriptions, and hashtags that form an integral part of the advertising material. The approval timeline takes approximately 3–4 months, as BPOM will generally request additional information or revisions during the verification and evaluation process. Applicants have 20 days to submit any such requested documents. BPOM may also conduct a reevaluation of advertisements that have already received approval, based on monitoring results or new information regarding the safety and quality of the advertised drug. This